Prospective Exploratory Study to Describe Hepatitis B Virus (HBV) Kinetics During Treatment With Telbivudine

Prospective Exploratory Study to Describe in CHB naïve and Non-naïve Patients, Hepatitis B Virus (HBV) Kinetics During the First 24 Weeks of Treatment With Telbivudine

This study will explore HBV kinetics in CHB patients during the first 24 weeks of treatment with telbivudine

Inclusion Criteria:

• Male or female, at least 18 years of age.
• Documented compensated HBeAg negative CHB defined by baseline HBV serology, DNA and ALT criteria.

Exclusion Criteria:

• Co-infection with HCV, HDV, or HIV.
• Prior therapy with nucleos(t)ides in NAÏVE patient and prior treatment with lamivudine in patients with suboptimal response to adefovir.
• History of hepatic decompensation
• History of malignancy
• Patient has one or more additional known primary or secondary causes of liver disease